GlassScriptPhysician profile
Brooke A Bering
NPI 1346555315
$6,454.57
in general payments reported to CMS, 2019-2025
27 companies · $1,607 in 2025
The $1,607 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,042 · 2022: $744 · 2023: $1,357 · 2024: $1,704 · 2025: $1,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,319 · Education: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,319.27 |
| Education | $349.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $775.24 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $764.56 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $563.99 | 2021-2025 | |
| Dermavant Sciences, INC. | $445.81 | 2023-2024 | Vtama |
| Lilly USA, LLC | $435.75 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $411.39 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $395.28 | 2021-2025 | Adbry |
| Genzyme Corporation | $367.77 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $338.31 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $303.05 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $252.63 | 2021-2025 | Dupixent, Libtayo |
| Almirall LLC | $230.78 | 2021-2025 | Klisyri |
| Incyte Corporation | $181.89 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $169.00 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $163.97 | 2021-2024 | Arazlo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $156.35 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Pfizer INC. | $130.74 | 2022-2025 | |
| Epi Health, LLC | $84.61 | 2021 | |
| Strata Skin Sciences, INC. | $56.51 | 2025 | Xtrac |
| Journey Medical Corporation | $43.43 | 2022-2023 | |
| Organon LLC | $39.10 | 2025 | Vtama |
| Amgen INC. | $29.99 | 2024 | Otezla |
| Dermira, INC. | $29.39 | 2021 | |
| Arcutis Biotherapeutics, INC. | $24.17 | 2023 | |
| Sebela Pharmaceuticals INC. | $22.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.35 | 2023 | Spevigo |
| Vyne Pharmaceuticals INC. | $16.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Bering listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.